Abstract:
:Cardiac toxicity has been implicated as the primary reason for excess non-breast cancer mortality in early breast cancer radiotherapy studies. Refinements in radiotherapy techniques have allowed for a considerable reduction of this risk in the majority of breast cancer patients. Recent large population-based studies confirmed an increase of cardiovascular death risk in patients irradiated for cancer of the left breast and in individuals exposed to relatively low (hitherto believed to be of no cardiovascular disease risk) doses of radiation, such as atomic bomb survivors or patients treated for various benign conditions. The issue of potential radiation-related cardiac damage may also be assuming a new significance due to the widespread use of other cardiotoxic agents, such as anthracyclines, paclitaxel and trastuzumab. The aim of this review is to summarize and critically analyze the available evidence on the impact of ionizing radiation on the cardiovascular system, with special attention to recent data demonstrating previously unrecognized adverse effects. This review discusses the pathology of radiation-related cardiovascular disease, its clinical presentation, risk factors and methods of assessment, as well as technical developments minimizing cardiac exposure. Epidemiological data are presented on the incidence of radiation-induced heart disease and cardiovascular mortality in various populations of patients irradiated for breast cancer and in individuals exposed to low radiation doses. Additionally, non-cardiac radiation-related vascular morbidity and mortality in breast cancer patients are addressed.
journal_name
Cancer Treat Revjournal_title
Cancer treatment reviewsauthors
Senkus-Konefka E,Jassem Jdoi
10.1016/j.ctrv.2007.07.011subject
Has Abstractpub_date
2007-10-01 00:00:00pages
578-93issue
6eissn
0305-7372issn
1532-1967pii
S0305-7372(07)00080-1journal_volume
33pub_type
杂志文章,评审abstract::Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. Howe...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2013.06.008
更新日期:2014-02-01 00:00:00
abstract:BACKGROUND:Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT). This review aims to give an overview of the hot topics concerning treatment, prognostic factors and new strategies in ad...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2012.09.007
更新日期:2013-02-01 00:00:00
abstract::When focusing on heart disease, most available studies split the two different parts of the adjuvant treatment, i.e., systemic therapies and radiation therapy, making it difficult to implement efficient strategies for preventing treatment-induced cardiac toxicity. This paper reviews the current understanding of treatm...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2010.08.007
更新日期:2011-06-01 00:00:00
abstract::Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Cl...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2018.11.002
更新日期:2019-01-01 00:00:00
abstract::The majority of stage III NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidati...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2018.04.001
更新日期:2018-05-01 00:00:00
abstract::Lung cancer has the highest frequency of brain dissemination compared to all other solid tumours. Classical treatment options such as brain irradiation have started to be questioned due to lack of survival benefit and risk for severe side effects. Oncogenic driven tumours have the highest frequency of brain disseminat...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2017.02.004
更新日期:2017-03-01 00:00:00
abstract::Cancer patients with pain may not respond to increasing doses of opioids because they develop adverse effects before achieving an acceptable analgesia, or the analgesic response is poor, despite a rapid dose escalation. Opioid switching may significantly improve the balance between analgesia and adverse effects. We co...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,meta分析,评审
doi:10.1016/j.ctrv.2006.03.001
更新日期:2006-06-01 00:00:00
abstract:GOALS OF THE WORK:Malignancy produces a state of physiologic stress that is characterized by a relative deficiency of glutamine, a condition that is further exacerbated by the effects of cancer treatment. Glutamine deficiency may impact on normal tissue tolerance to antitumor treatment, and may lead to dose reductions ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(03)00133-6
更新日期:2003-12-01 00:00:00
abstract::Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus, we conducted a toxicity-attribution workshop in Silver Springs MD to develop guidance for improving ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2019.04.004
更新日期:2019-06-01 00:00:00
abstract::Approximately 5-10% of breast cancer cases might be inheritable, up to 30% of which are due to BRCA1/2 mutations. During the past few years and thanks to technology evolution, we have been witnesses of an intensive search of additional genes with similar characteristics, under the premise that successful gene discover...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2014.10.008
更新日期:2015-01-01 00:00:00
abstract::Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Distinct failure patterns exist, despite the routine adoption of contemporary treatment modalities such as intensity modulated radiotherapy and systemic chemotherapy. Concurrent chemoradiotherapy (CCR...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2020.101995
更新日期:2020-04-01 00:00:00
abstract::Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2014.06.009
更新日期:2014-09-01 00:00:00
abstract::The prognosis of advanced pancreatic adenocarcinoma is still poor nowadays. Gemcitabine in monotherapy (30-min infusion) has been the standard of treatment during the last decade, and many clinical trials have failed to demonstrate an improvement in overall survival (OS) with the addition of different drugs to gemcita...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.11.007
更新日期:2009-06-01 00:00:00
abstract::Arc therapies have gained widespread clinical interest in radiation oncology over the past decade. Arc therapies have several potential advantages over standard techniques such as intensity-modulated radiation therapy, with implications for patients, administrators, and oncologists. This review focuses on the rational...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2010.01.004
更新日期:2010-08-01 00:00:00
abstract::In a clinical phase II study 151 patients with refractory malignant diseases were treated with ifosfamide (60 mg/kg/day i.v. days 1-5, q 21-28 days). Altogether, 490 courses of treatment were given, 92 with conventional prophylactic measures (continuous infusion of 3-4 litre physiological saline plus alkalinization of...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/s0305-7372(83)80013-9
更新日期:1983-09-01 00:00:00
abstract:BACKGROUND:The colony-stimulating factors (CSFs) are widely utilized to prevent neutropenic complications in both adults and children, but randomized controlled trials in the pediatric setting have reported varied results. A systematic review of the literature and meta-analysis were conducted to definitively assess the...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,meta分析,评审
doi:10.1016/j.ctrv.2006.03.002
更新日期:2006-06-01 00:00:00
abstract::Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology commun...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2018.06.001
更新日期:2018-09-01 00:00:00
abstract:PURPOSE:Neoadjuvant chemotherapy followed by surgery (NACT + S) has been compared with definitive chemoradiothherapy (CRT) in randomized clinical trials (RCTs) in stage IB2, IIA and IIB cervical cancer (1994 Figo stage). Our aim was to evaluate efficacy and toxicity of NACT + S and CRT and identify differences in clini...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,meta分析
doi:10.1016/j.ctrv.2019.101945
更新日期:2020-02-01 00:00:00
abstract::Metastatic colorectal cancer remains a public-health issue on a global scale. With development of a new generation of cytotoxic agents, survival has improved for patients with metastatic disease. How to maximize the benefit of chemotherapy with acceptable toxicity remains incompletely answered. Hepatic resection can p...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2006.07.005
更新日期:2006-11-01 00:00:00
abstract::Prostate cancer is a significant cause of morbidity and mortality in the United States and Europe. The natural ageing of the population as well as the continued and widespread use of diagnostic tests such as prostate specific antigen (PSA), has led to an increase in the numbers of men diagnosed with localised prostate...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(03)00096-3
更新日期:2003-06-01 00:00:00
abstract::During the last decade, important progress has been made in the surgical treatment of malignant liver tumors in children. For hepatoblastoma, there is a general consensus for combining surgical resection with neoadjuvant (and adjuvant) chemotherapy. Long-term disease-free survival of around 85-90% can be achieved for ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2010.02.013
更新日期:2010-06-01 00:00:00
abstract::Galectins belong to a family of carbohydrate-binding proteins with an affinity for β-galactosides. Galectin-1 is differentially expressed by various normal and pathologic tissues and displays a wide range of biological activities. In oncology, galectin-1 plays a pivotal role in tumor growth and in the multistep proces...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2013.07.007
更新日期:2014-03-01 00:00:00
abstract::Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease (metastases). The invasive ability of tumour cells plays a key role in CaP met...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2007.06.003
更新日期:2007-10-01 00:00:00
abstract::TP53 (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild-type (WT) p53 is inactivated by interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alte...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2014.10.004
更新日期:2014-12-01 00:00:00
abstract::Metastatic malignant melanoma remains one of the most dreaded skin cancers worldwide. Numerous factors contribute to its resistance to hosts of treatment regimes and despite significant scientific advances over the last decade in the field of chemotherapeutics and melanocytic targets, there still remains the need for ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2010.11.007
更新日期:2011-10-01 00:00:00
abstract::Since its first regulatory approval more than 10 years ago, oncologists have gained wide experience in using the oral fluoropyrimidine, capecitabine, as monotherapy or in combination with other agents and the body of evidence supporting these approaches continues to grow. Alongside this increasing experience has been ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2009.06.003
更新日期:2009-11-01 00:00:00
abstract:PURPOSE:To summarize and define the methodological quality of primary research findings obtained in exercise interventions, aimed at improving physical function or psychological well-being in patients treated for haematological malignancies. METHODS:Relevant trials were identified through a computerized Mesh-search in...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.09.008
更新日期:2009-04-01 00:00:00
abstract::In metastatic colorectal cancer (mCRC), fluorouracil-based combination therapy with oxaliplatin or irinotecan is the mainstay of first-line treatment. Patient survival has been significantly improved with the introduction of monoclonal antibodies against VEGF (bevacizumab), VEGFR2 (ramucirumab) or EGFR (cetuximab or p...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2016.10.006
更新日期:2016-12-01 00:00:00
abstract::Langerhans cell histiocytosis (LCH) is a rare proliferative disorder of cells with the phenotype of activated Langerhans cells. The diagnosis of LCH is often delayed or missed. Many questions about LCH remain to be answered, including whether it is caused by a malignancy or by immune dysregulation. Data from the early...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2010.02.012
更新日期:2010-06-01 00:00:00
abstract:PURPOSE:Dysphagia is a debilitating complication in head and neck cancer patients (HNCPs) that may cause a high mortality rate for aspiration pneumonia. The aims of this paper were to summarize the normal swallowing mechanism focusing on its anatomo-physiology, to review the relevant literature in order to identify the...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2012.04.002
更新日期:2012-12-01 00:00:00